The incidence and risk factors of central nervous system (CNS) involvement in peripheral T-cell lymphomas (PTCLs) are still unclear.
introduction Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of malignancies derived from mature or post-thymic T cells and natural killer (NK) cells, representing 12% of all non-Hodgkin lymphomas (NHL) in Western countries [1] . However, in the Asian population, the incidence of the disease is known to be higher [2, 3] . Because of its rare incidence and the lack of standardized treatment strategies, the prognosis of the disease is worse than that of B-cell lymphomas and the natural course is not well-understood.
Many authors have reported the risk factors and the prognostic value of involvement of the central nervous system (CNS) in patients with B-cell lymphoma [4] [5] [6] . Patients with aggressive lymphomas such as lymphoblastic and Burkitt's lymphoma are at high risk for CNS involvement (30-50%), and routine CNS prophylaxis for these diseases is recommended. In aggressive NHLs, involved sites, including testis [7] , paranasal sinus [8] , breast [9] and bone marrow [10] , are also known to affect the incidence of CNS involvement. Other clinical factors including the presence of B symptoms, high lactate dehydrogenase (LDH), two or more extranodal involvements, advanced stage, low albumin level and young age are reported to have an adverse influence on CNS involvement [4] . The prognoses of patients with CNS disease are dismal, with a median survival of 2-6 months, which is even shorter than that of patients with non-CNS relapse [11] .
With respect to PTCLs, few studies have reported on the incidence of CNS involvement [12, 13] and no study has suggested specific risk factors for CNS involvement in the disease. This lack of information may be attributed to the low incidence and various subtypes of PTCLs. However, as novel treatment strategies enable patients with PTCLs to survive longer, cases of CNS involvement may also be increasing in frequency. Therefore, identification of risk factors for CNS involvement in patients with PTCLs is necessary.
Recently, Kim et al. reported that the incidence of CNS involvement in extranodal NK/T-cell lymphoma was 5.76% and suggested that a high NK/T-cell lymphoma prognostic index (NKPI) score [14] could be a predictive factor [15, 16] . However NK/T cell lymphoma differs from other PTCLs in that it frequently originates from the oronasal or aerodigestive areas. In this study, we carried out a retrospective analysis of the clinical features, predictive factors and prognostic role of CNS involvement in patients with PTCLs.
patients and methods patients
Patients older than 15 years who were diagnosed with mature T-cell lymphoma from June 1995 to August 2009 were included in the analysis. Based on the World Health Organization classification for mature T-cell neoplasms, we included patients with PTCL, not otherwise specified (NOS), anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), hepatosplenic T-cell lymphoma (HSTL) and enteropathy-associated T-cell lymphoma (EATL). All of the pathologic diagnoses were based on hematoxylin and eosin staining, and immunostaining for antigens such as CD3, CD4, CD30 and CD56. If needed, further analysis for T-cell receptor class or Epstein-Barr virus in situ hybridization can be carried out.
The following subtypes were excluded: T-cell leukemias, NK cell leukemia, lymphoblastic lymphoma, extranodal NK/T-cell lymphoma, primary cutaneous PTCLs, mycosis fungoides, Sezary syndrome and chronic lymphoproliferative disorder of NK cells. Among 517 patients with mature T-cell lymphoma, 228 patients were included in the analysis (Figure 1 ). This study was approved by the institutional review board of Association for the Accreditation of Human Research Protection Program approved center. The study was carried out in accordance with the precepts of the Declaration of Helsinki.
diagnosis of CNS disease
CNS disease was defined as any evidence of CNS involvement any time after initial diagnosis. CNS disease was divided into two categories; an isolated CNS involvement without evidence of systemic residual disease and combined involvement of CNS with other systemic involvement.
The types of CNS disease consisted of parenchymal metastases and leptomeningeal invasion. Parenchymal disease was diagnosed by magnetic resonance imaging (MRI) or a brain computed tomography scan. Leptomeningeal involvement was diagnosed on the basis of cerebrospinal fluid (CSF) cytology and three diagnostic criteria were applied. These criteria were (i) presence of malignant lymphomatous cells in the CSF, (ii) presence of suspicious cells with increased protein level in the CSF or (iii) presence of suspicious cells with suggestive findings of leptomeningeal seeding on MRI. The definition of suspicious cells was lymphocytes with an atypical morphology.
clinical parameters
We retrospectively collected clinical parameters from patients' medical records, including age, sex, final pathologic diagnosis, date and the regimen of the first treatment, date of last visit or expiration, performance status (PS), Ann Arbor stage, presence of extranodal involvement, bone marrow Table 2 . Among the histologic subtypes, ALCL had the highest proportion of CNS disease (5/32, 15.6%). Two patients were positive for ALK, two were negative and one was not examined for ALK status. None of the patients with HSTL (0/8, 0%) and a relatively small portion of patients with AITL (3/52, 5.8%) had CNS disease. However, there was no statistically significant difference among the histologic subgroups (P = 0.348).
The clinical manifestations of CNS disease are summarized in Table 3 . Fourteen (70.0%) patients had leptomeningeal involvement, five (25.0%) had parenchymal metastasis and one (5.0%) had both. Two (10.0%) patients had isolated CNS involvement and 18 (90.0%) had CNS disease along with another systemic disease. Both patients with isolated CNS involvement had parenchymal metastasis and among the 18 patients with combined CNS and systemic involvement, 14 had leptomeningeal seeding, 3 had parenchymal metastasis and 1 had both types of involvement.
The median time to CNS disease was 6.05 months (range 0.0-71.2). The clinical features of individual patients with CNS disease and their courses are summarized in Table 4 . Two patients had CNS involvement at the time of initial diagnosis, 7 patients had recurring disease of the CNS after complete remission after systemic chemotherapy or autologous stem cell transplantation and 11 patients had CNS disease developed during the first-line or salvage chemotherapy with residual systemic disease.
Survival of the patients with CNS involvement was significantly shorter than that of patients without CNS involvement (P = 0.009), with median overall survival of 7.60 months [95% confidence interval (CI) 4.92-10.28] versus 27.43 months (95% CI of 0.00-57.38), respectively (Figure 2) . Two patients died from progression of CNS disease, 11 patients died of systemic progression and 7 patients were lost during follow-up. 
risk factor analysis
An increased risk for CNS involvement was associated with increased LDH level [P = 0.015, relative risk (RR) 7.282, 95% CI 1.472-36.033] and involvement of the paranasal sinus (P = 0.029, RR 3.514, 95% CI 1.134-10.893) in univariate analysis. Risk factors of CNS involvement in B-cell lymphoma, such as bone marrow involvement, advanced age or Ann Arbor stage and extranodal involvement, did not increase the risk for CNS involvement in cases of PTCL (Table 5) .
In multivariate analysis, both the increased LDH level [P = 0.011, hazard ratio (HR) = 6.716, 95% CI 1.548-29.131] and involvement of the paranasal sinus (P = 0.008, HR 3.784, 95% CI 1.420-10.083) were predictive factors for CNS disease. Comparing the patients with zero, one or two risk factors, the incidences of CNS involvement were significantly different among the groups (Figure 3) . One out of 75 (1.3%) patients without any risk factor, 14 out of 132 (10.6%) patients with one risk factor and 5 out of 21 (23.8%) patients with both risk factors had CNS disease (P = 0.010).
discussion
The risk of CNS involvement is 30-50% in patients with aggressive lymphomas such as lymphoblastic lymphoma/ leukemia or Burkitt's lymphoma [17] [18] [19] , and 5-10% in patients with diffuse large B-cell lymphoma [4] .
In cases of PTCLs, there have been few reports of the incidence of CNS involvement, risk factors or prognostic role on overall survival. Kim et al. reported that 5.76% of secondary CNS involvement in patients with extranodal NK/T cell lymphoma, nasal type and group III/IV NKPI [20] has statistical power to predict secondary CNS disease.
In our study, 20 out of 228 patients (8.77%) had CNS disease. Patients with ALCL had the highest incidence (5/32, 15.6%), and among 32 patients with ALCL, ALK status was examined in 23 patients. Twelve patients were ALK negative and 11 were ALK positive. Although ALK-positive ALCL is known to have a better prognosis, there was no difference in CNS involvement between the ALK-positive and ALK-negative groups (P = 0.924).
Patients with AITL had the least CNS involvement (3/52, 5.8%). In many cases, patients with AITL have advanced age, B symptoms, poor PS, elevated LDH and advanced stage, all of which are known to adversely affect the prognoses of the patients [21, 22] . However, according to our study, CNS involvement seems to be relatively rare in AITL. For cases of HSTL, which is also known to have an aggressive clinical course such as visceral organ/extranodal involvement or pancytopenia, there was no CNS involvement. As our study analyzed only six patients with HSTL, a larger clinical study is necessary to determine the CNS involvement with HSTL.
IPI and PIT have been applied to various kinds of PTCLs, and many have a reported prognostic value [3, 21, 23, 24] . In our study, however, neither IPI nor PIT was related to CNS disease, which may be the result of a lack of predictive roles of age, advanced stage, extranodal involvement, PS or bone marrow involvement. The known incidence of CNS involvement and risk factors according to histologic subtypes are summarized in Table 6 .
The median time to first CNS involvement in our study was 6.05 months (range 0.0-71.2 months). Using the results of previous reports, this is somewhat shorter than that of the Bcell lymphomas (5-12 months [4] ) and is similar to that of extranodal NK/T cell lymphoma, nasal type (6.03 months [20] ).
Seven patients had CNS disease that relapsed without evidence of systemic residual disease. The longest disease-free interval between systemic remission and CNS relapse was 32.13 months, where the primary disease was PTCL-NOS in testis. Another patient with testis involvement of PTCL-NOS had CNS relapse after 9 months of complete remittance. Of 228 patients, three had testicular involvement and two had CNS disease. This suggests that the testis could also be a sanctuary The median survival duration of patients with CNS disease was significantly shorter than that of patients without CNS disease. Among 13 patients with CNS disease whose clinical courses were followed up, 11 patients died of systemic progression and only two died of CNS progression. CNS relapse might be a manifestation of systemic progression, or untreated malignant lymphocytes could remain in the brain parenchymal tissue or CSF.
Fourteen out of 132 (10.6 %) patients with either risk factor (elevated LDH level, paranasal sinus involvement) and 5 out of 21 (23.8%) patients with both risk factors had CNS involvement. This implies that screening and follow-up examinations for CNS involvement should be considered in patients with any risk factor, although there is no consensus on efficacy, what therapeutic agents or methods should be used for the treatment [4] . Further large-scaled analysis is necessary on this issue.
In summary, elevated serum LDH level and involvement of the paranasal sinus are risk factors for CNS involvement in patients with PTCLs. CNS prophylaxis might be considered for CNS, central nervous system; NK, natural killer; PTCL, peripheral T-cell lymphoma; IPI, international prognostic index; NKPI, NK/T-cell lymphoma prognostic index; LDH, lactate dehydrogenase. 
